Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis

Mahdi Abastabar, Iman Haghani, Tahereh Shokohi, Mohammad Taghi Hedayati, Seyed Reza Aghili, Ali Jedi, Sulmaz Dadashi, Shafigheh Shabanzadeh, Tahereh Hosseini, Narges Aslani, Jacques F. Meis, Hamid Badali
Mahdi Abastabar
aInvasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iman Haghani
aInvasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahereh Shokohi
aInvasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tahereh Shokohi
Mohammad Taghi Hedayati
aInvasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohammad Taghi Hedayati
Seyed Reza Aghili
aInvasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Jedi
bStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sulmaz Dadashi
bStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shafigheh Shabanzadeh
aInvasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahereh Hosseini
bStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narges Aslani
cDepartment of Medical Parasitology and Mycology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques F. Meis
dCentre of Expertise in Mycology Radboud University Medical Centre/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
eDepartment of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jacques F. Meis
Hamid Badali
aInvasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
fDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hamid Badali
DOI: 10.1128/AAC.01632-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • TABLE 1

    In vitro susceptibilities of five antifungal drugs against different fungal isolates from patients with onychomycosisa

    GenusSpecies (no. of isolates)MIC parameterMIC (µg/ml) for:
    TavaboroleVoriconazoleItraconazoleFluconazoleTerbinafine
    CandidaC. parapsilosis (27)Range2 to >160.008 to >160.125 to >160.0625 to >644 to >4
    MIC50160.01610.54
    MIC90160.25284
    GM14.490.062.461.714
    C. tropicalis (10)Range8 to >160.0625 to >0.51 to >80.25 to >644 to >4
    MIC50160.032224
    MIC90160.254164
    GM14.490.062.461.714
    C. albicans (7)Range4 to >160.008 to >0.0160.25 to 160.125 to >44 to >4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    C. krusei (4)Range8 to 160.0625 to 0.0160.5 to 10.5 to 164 to >4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    C. orthopsilosis (2)Range160.01610.25 to 14 to >4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    C. guilliermondii (1)Range160.12544>4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    C. glabrata (1)Range160.12542>4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    All Candida strains (52)Range2 to >160.008 to >160.125 to >160.0625 to >164 to >4
    MIC50160.032114
    MIC90160.25484
    GM12.580.030.770.744
    AspergillusA. flavus (36)Range0.5 to 160.0625 to 0.50.0625 to 116 to >640.032 to 8
    MIC5020.250.125640.5
    MIC9040.50.25644
    GM1.80.210.1345.250.59
    A. terreus (21)Range1 to 40.125 to 10.0625 to 0.25640.032 to 8
    MIC5020.250.016644
    MIC90410.125648
    GM2.40.330.03641.8
    A. niger (17)Range0.5 to 160.0625 to 20.0625 to >1632 to >640.125 to 8
    MIC5010.250.032320.5
    MIC90160.51644
    GM1.920.250.242.250.81
    A. tubingensis (8)Range1 to 80.125 to 10.25 to 1640.25 to 8
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    A. oryzae (3)Range1 to 80.0625 to 0.1250.032 to 0.12532 to 640.0625 to 1
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    A. fumigatus (2)Range2 to 160.0625 to 0.250.0625 to 0.564 to >644 to >4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    A. uvarum (1)Range0.50.1250.016>644
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    All Aspergillus strains (88)Range0.5 to 160.0625 to 20.016 to >160.5 to >640.032 to >4
    MIC5020.250.125641
    MIC9040.50.5644
    GM20.240.150.790.92
    DermatophytesT. interdigitale (8)Range4 to 160.016 to 0.06250.0625 to 0.12516 to 320.008 to 4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    T. rubrum (5)Range8 to 160.016 to >160.016 to >162 to 160.008 to >4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    T. tonsurans (1)Range80.0320.032160.004
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    All dermatophyte strains (14)Range4 to 160.016 to >160.016 to >162 to 320.004 to >4
    MIC5080.0320.0625160.004
    MIC90160.0320.0625320.008
    GM9.280.020.0310.240.007
    FusariumF. proliferatum (8)Range16 to >161 to 4>1664 to >64>4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    F. verticillioides (2)Range8-161->168->16>640.032- >4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    F. solani (2)Range16 to >160.5 to 2>16>64>4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    Fusarium sp. (2)Range162>16>64>4
    MIC50NDNDNDNDND
    MIC90NDNDNDNDND
    GMNDNDNDNDND
    All Fusarium strains (14)Range8 to >160.5 to >168 to >1664 to >640.032 to >4
    MIC501628644
    MIC901648644
    GM14.6728644
    • ↵aGM, geometric mean; MIC50, concentration at which 50% of the isolates were inhibited; MIC90, concentration at which 90% of the isolates were inhibited; ND, not determined.

  • TABLE 2

    In vitro susceptibilities of 5 antifungal drugs against 170 fungal isolates from different patients with onychomycosisb

    Antifungal drugMIC (µg/ml)aMIC rangeMIC50MIC90GM
    0.0040.0080.0160.0310.0630.1250.250.512481632>64
    Tavaborole520451819630.5 to 164164.44
    Voriconazole427141630302589430.008 to >160.12510.13
    Itraconazole19101823202024782190.016 to >160.2520.2
    Fluconazole17511710521281020.0625 to >644643.67
    Terbinafine1093112101311118910.004 to >4240.74
    • ↵a Numbers in boldface are modal values.

    • ↵b GM, geometric mean; MIC50, concentration at which 50% of the isolates were inhibited; MIC90, concentration at which 90% of the isolates were inhibited.

PreviousNext
Back to top
Download PDF
Citation Tools
Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis
Mahdi Abastabar, Iman Haghani, Tahereh Shokohi, Mohammad Taghi Hedayati, Seyed Reza Aghili, Ali Jedi, Sulmaz Dadashi, Shafigheh Shabanzadeh, Tahereh Hosseini, Narges Aslani, Jacques F. Meis, Hamid Badali
Antimicrobial Agents and Chemotherapy Nov 2018, 62 (12) e01632-18; DOI: 10.1128/AAC.01632-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis
Mahdi Abastabar, Iman Haghani, Tahereh Shokohi, Mohammad Taghi Hedayati, Seyed Reza Aghili, Ali Jedi, Sulmaz Dadashi, Shafigheh Shabanzadeh, Tahereh Hosseini, Narges Aslani, Jacques F. Meis, Hamid Badali
Antimicrobial Agents and Chemotherapy Nov 2018, 62 (12) e01632-18; DOI: 10.1128/AAC.01632-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

tavaborole
antifungal
onychomycosis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596